David M. SPENCER,Aaron Edward Foster, SR.,Joseph Henri Bayle,Kevin M. Slawin,Matthew R. Collinson-Pautz
申请号：
US14968737
公开号：
US20160166613A1
申请日:
2015.12.14
申请国别(地区):
US
年份:
2016
代理人:
摘要：
The technology relates in part to methods for controlling elimination of therapeutic cells, for example, cells that express a chimeric antigen receptor. The technology further relates to a two-step method of controlling destruction of therapeutic cells in a patient following an adverse event. The two-step system may include a rapamycin or rapamycin analog-based level of control and a second, rimiducid, level of control. The technology also relates in part to methods for cell therapy using cells that express the inducible caspase polypeptide and the rapamycin-sensitive polypeptide, where the proportion of therapeutic cells eliminated by apoptosis is related to the choice and amount of the administered ligand.
